Display options
Cite
Maggiolo F, Colombo GL, Di Matteo S, et al. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015;6:53-60doi: 10.2147/PROM.S63586.
Maggiolo, F., Colombo, G. L., Di Matteo, S., Bruno, G. M., Astuti, N., Di Filippo, E., Masini, G., & Bernardini, C. (2015). Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient related outcome measures, 653-60. https://doi.org/10.2147/PROM.S63586
Maggiolo, Franco, et al. "Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation." Patient related outcome measures vol. 6 (2015): 53-60. doi: https://doi.org/10.2147/PROM.S63586
Maggiolo F, Colombo GL, Di Matteo S, Bruno GM, Astuti N, Di Filippo E, Masini G, Bernardini C. Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015. PMID: 25733942; PMCID: PMC4337626.
Copy Download .nbib Format: NLM
Share it on

Patient Relat Outcome Meas. 2015 Feb 17;6:53-60. doi: 10.2147/PROM.S63586. eCollection 2015.

Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation.

Patient related outcome measures

Franco Maggiolo, Giorgio L Colombo, Sergio Di Matteo, Giacomo M Bruno, Noemi Astuti, Elisa Di Filippo, Giulia Masini, Claudia Bernardini

Affiliations

  1. Division of Infectious Diseases, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy.
  2. University of Pavia, Department of Drug Sciences, Pavia, Italy ; SAVE Studi Analisi Valutazioni Economiche, Milan, Italy.
  3. SAVE Studi Analisi Valutazioni Economiche, Milan, Italy.

PMID: 25733942 PMCID: PMC4337626 DOI: 10.2147/PROM.S63586

Abstract

OBJECTIVES: Costs may play a role in deciding how and when to start highly active antiretroviral therapy (HAART) in a naïve patient. The aim of the present study was to assess the cost- effectiveness of treatment with HAART in a large clinical cohort of naïve adults to determine the potential role of single-tablet regimens in the management of patients with human immunodeficiency virus (HIV). An incremental cost-effectiveness ratio analysis was performed, including a quality-adjusted life year approach.

RESULTS: In total, 741 patients (females comprising 25.5%) were retrospectively included. The mean age was 39 years, the mean CD4 cell count was 266 cells/μL, and the mean viral load was 192,821 copies/mL. The most commonly used backbone was tenofovir + emtricitabine (77.6%); zidovudine + lamivudine was used in 10%, lamivudine + abacavir in 3%, and other nucleoside reverse transcriptase inhibitor (NRTI) or NRTI-free regimens in 9.4% of patients. NNRTIs were used in 52.8% of cases, boosted protease inhibitors in 44.1%, and unboosted protease inhibitors and integrase inhibitors in 0.7% and 2.4%, respectively. Starting therapy at CD4 >500 cells/μL and CD4 351-500 cells/μL rather than at <201 cells/μL was the more cost-effective approach. The same consideration was not true comparing current indications with the possibility to start HAART at any CD4 value (eg, >500 cells per μL); in this case, the incremental cost-effectiveness ratio value was €199,130 per quality-adjusted life year gained, a higher value than the one suggested in guidelines. The single-tablet regimen (STR) invariably dominated any other therapeutic approach. Sensitivity analysis was performed, and starting right away with an STR was cost-effective even when compared with therapeutic strategies contemplating STR as simplification.

CONCLUSION: By integrating clinical data with economic variables, our study offers an estimate of the cost-effectiveness of the various first-line treatment strategies for patients infected with HIV and provides significant evidence to be used in future prospective pharmacoeconomic evaluations.

Keywords: cost-effectiveness; highly active antiretroviral therapy; quality-adjusted life years; single-tablet regimen

References

  1. Clinicoecon Outcomes Res. 2013 Oct 03;5:489-96 - PubMed
  2. Lancet. 2010 Aug 14;376(9740):532-9 - PubMed
  3. Ther Clin Risk Manag. 2012;8:377-84 - PubMed
  4. Clin Infect Dis. 2009 Feb 15;48(4):484-8 - PubMed
  5. Curr Opin HIV AIDS. 2011 Dec;6 Suppl 1:S21-30 - PubMed
  6. J Acquir Immune Defic Syndr. 2009 Apr 15;50(5):529-36 - PubMed
  7. HIV Clin Trials. 2004 Sep-Oct;5(5):294-304 - PubMed
  8. Pharmacoeconomics. 2010;28 Suppl 1:35-47 - PubMed
  9. Ther Clin Risk Manag. 2014;10:9-15 - PubMed
  10. Clinicoecon Outcomes Res. 2013;5:59-68 - PubMed
  11. Patient Prefer Adherence. 2012;6:427-33 - PubMed
  12. AIDS Patient Care STDS. 2004 Nov;18(11):644-57 - PubMed
  13. Patient Prefer Adherence. 2010 May 13;4:115-25 - PubMed
  14. Lancet. 2008 Jul 26;372(9635):293-9 - PubMed
  15. Clin Infect Dis. 2005 Jan 1;40(1):158-63 - PubMed
  16. Patient Prefer Adherence. 2011;5:357-67 - PubMed
  17. Expert Rev Pharmacoecon Outcomes Res. 2008 Apr;8(2):165-78 - PubMed
  18. Eur J Health Econ. 2010 Aug;11(4):405-12 - PubMed
  19. N Engl J Med. 2011 Aug 11;365(6):493-505 - PubMed
  20. JAMA. 2012 Jul 25;308(4):387-402 - PubMed
  21. Res Social Adm Pharm. 2012 Mar-Apr;8(2):157-65 - PubMed
  22. Lancet. 2010 Jul 3;376(9734):49-62 - PubMed
  23. New Microbiol. 2011 Apr;34(2):109-46 - PubMed
  24. AIDS. 2011 Jan 28;25(3):279-90 - PubMed
  25. Clinicoecon Outcomes Res. 2012;4:245-52 - PubMed
  26. J Infect Dis. 2008 Apr 15;197(8):1145-55 - PubMed
  27. AIDS. 2008 Oct 1;22(15):1951-60 - PubMed
  28. HIV Clin Trials. 2002 Sep-Oct;3(5):371-8 - PubMed

Publication Types